AU2016227486A1 - Angiotensin ll receptor agonist for treating pulmonary fibrosis - Google Patents

Angiotensin ll receptor agonist for treating pulmonary fibrosis Download PDF

Info

Publication number
AU2016227486A1
AU2016227486A1 AU2016227486A AU2016227486A AU2016227486A1 AU 2016227486 A1 AU2016227486 A1 AU 2016227486A1 AU 2016227486 A AU2016227486 A AU 2016227486A AU 2016227486 A AU2016227486 A AU 2016227486A AU 2016227486 A1 AU2016227486 A1 AU 2016227486A1
Authority
AU
Australia
Prior art keywords
composition
use according
angiotensin
receptor
pulmonary fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2016227486A
Other languages
English (en)
Inventor
Bjorn Dahlof
Anders Ljunggren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vicore Pharma AB
Original Assignee
Vicore Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma AB filed Critical Vicore Pharma AB
Publication of AU2016227486A1 publication Critical patent/AU2016227486A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016227486A 2015-03-02 2016-03-02 Angiotensin ll receptor agonist for treating pulmonary fibrosis Withdrawn AU2016227486A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126880P 2015-03-02 2015-03-02
US62/126,880 2015-03-02
PCT/GB2016/050552 WO2016139475A1 (en) 2015-03-02 2016-03-02 Angiotensin ii receptor agonist for treating pulmonary fibrosis

Publications (1)

Publication Number Publication Date
AU2016227486A1 true AU2016227486A1 (en) 2017-08-17

Family

ID=55646777

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016227486A Withdrawn AU2016227486A1 (en) 2015-03-02 2016-03-02 Angiotensin ll receptor agonist for treating pulmonary fibrosis

Country Status (11)

Country Link
US (1) US20180078529A1 (enExample)
EP (1) EP3265082A1 (enExample)
JP (1) JP2018507244A (enExample)
KR (1) KR20170122754A (enExample)
CN (1) CN107405406A (enExample)
AU (1) AU2016227486A1 (enExample)
BR (1) BR112017018715A2 (enExample)
CA (1) CA2977445A1 (enExample)
HK (1) HK1244232A1 (enExample)
MX (1) MX2017010993A (enExample)
WO (1) WO2016139475A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017204163A1 (ja) * 2016-05-23 2017-11-30 国立研究開発法人国立循環器病研究センター 肺障害の予防または抑制用医薬
WO2019014710A1 (en) * 2017-07-17 2019-01-24 Monash University ANGIOTENSIN RECEPTOR AGONISTS AND USES THEREOF
EP3820498A1 (en) 2018-06-14 2021-05-19 University College Cork-National University of Ireland Cork Peptide for disease treatment
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
GB201913603D0 (en) 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
GB201917327D0 (en) 2019-11-28 2020-01-15 Vicore Pharma Ab New pharmaceutical use
PH12022552413A1 (en) 2020-03-19 2024-01-08 Vicore Pharma Ab Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
US11123329B1 (en) * 2020-03-23 2021-09-21 Vicore Pharma Ab Use of angiotensin II type 2 receptor agonist
GB202006081D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006074D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202007122D0 (en) 2020-05-14 2020-07-01 Vicore Pharma Ab New process
GB202013721D0 (en) 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
GB202104033D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
WO2022200785A1 (en) 2021-03-23 2022-09-29 Vicore Pharma Ab Selective angiotensin ii receptor ligands
GB202104038D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
MX2024000518A (es) 2021-07-09 2024-01-31 Vicore Pharma Ab Nuevos compuestos selectivos de angiotensina ii.
GB202115303D0 (en) 2021-10-25 2021-12-08 Vicore Pharma Ab New formulation
WO2023140350A1 (ja) * 2022-01-21 2023-07-27 国立大学法人 長崎大学 臓器の線維化抑制用医薬組成物
JP2025506498A (ja) 2022-02-10 2025-03-11 ヴィコール ファルマ アーベー 特発性肺線維症の処置のためのブロキシブチドの使用
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use
CN114869866B (zh) * 2022-05-05 2024-02-20 珠海瑞思普利医药科技有限公司 一种治疗特发性肺纤维化的干粉吸入剂及其制备方法
IE20230600A3 (en) * 2022-12-22 2025-09-24 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease
EP4648850A1 (en) 2023-01-09 2025-11-19 Vicore Pharma AB Selective angiotensin ii compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
DK1395566T3 (da) 2001-05-31 2008-01-07 Vicore Pharma Ab Tricycliske forbindelser, der er nyttige som angiotensin Il-agonister
US8835471B2 (en) * 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
EP2832357A1 (en) * 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selective AT2 receptor agonists for use in treatment of cachexia

Also Published As

Publication number Publication date
KR20170122754A (ko) 2017-11-06
BR112017018715A2 (pt) 2018-04-17
WO2016139475A1 (en) 2016-09-09
MX2017010993A (es) 2018-04-11
JP2018507244A (ja) 2018-03-15
EP3265082A1 (en) 2018-01-10
HK1244232A1 (zh) 2018-08-03
CN107405406A (zh) 2017-11-28
CA2977445A1 (en) 2016-09-09
US20180078529A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
US20180078529A1 (en) Angiotensin ii receptor agonist for treating pulmonary fibrosis
JP6097888B2 (ja) 新規使用
US12233068B2 (en) Combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
US10016397B2 (en) Selective AT2 receptor agonists for use in treatment of cachexia
WO2016107879A2 (en) New use of angiotensin ii receptor agonists
CA3236757A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
US11931341B2 (en) Compositions and methods for the treatment and prevention of muscular dystrophy
WO2016193883A1 (en) Sacubitril and valsartan for treating metabolic disease
US20250312332A1 (en) Treatment of muscle fibrosis
WO2014122638A2 (en) Thalidomide and thalidomide analogues for the stimulation in human/animals of stem cell factor to increase regenerative potential in aging conditions
HK40122845A (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
HK40118402A (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
CN114469960A (zh) 丹参酮iia磺酸钠在制备治疗肺动脉重塑病症药物中的应用

Legal Events

Date Code Title Description
MK12 Application lapsed section 141(1)/reg 8.3(2) - applicant filed a written notice of withdrawal